FDA sets the stage for adcomm on Sanofi, AZ's RSV prospect later this week

As GSK and Pfizer look to roll out their adult respiratory syncytial virus (RSV) vaccines later this year, Sanofi and AstraZeneca hope to join them on the market with an antibody designed to protect infants. But first, the partners will need to pass several regulatory milestones, including an FDA advisory committee discussion set for later this week.